CCM
CYTK icon

Coldstream Capital Management’s Cytokinetics CYTK Stock Holding History

Coldstream Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479K Sell
5,627
-318
-5% -$22.8K 0.01% 756
2026
Q1 		$392K Buy
5,945
+625
+12% +$39.7K ﹤0.01% 832
2025
Q4 		$338K Buy
5,320
+568
+12% +$35.3K ﹤0.01% 861
2025
Q3 		$261K Buy
+4,752
New +$196K ﹤0.01% 1004
2025
Q2 		– Sell
-2,869
Closed -$115K – 1663
2025
Q1 		$115K Buy
+2,869
New +$132K ﹤0.01% 1275

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coldstream Capital Management's CYTK Position: Q2 2026 in Review

Coldstream Capital Management reduced its Cytokinetics (CYTK) stake by 5.3% in Q2 2026, selling an estimated $22.8K and leaving 5,627 shares worth $479K. The position accounts for 0.01% of the portfolio, ranked #756.

Coldstream Capital Management first reported a position in CYTK in Q1 2025 and has held it in 5 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Coldstream Capital Management held 5,627 shares of Cytokinetics worth $479K as of Q2 2026.
  • Coldstream Capital Management sold 318 Cytokinetics shares in Q2 2026, an estimated $22.8K.
  • Cytokinetics made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #756 holding.
  • Coldstream Capital Management first reported a position in Cytokinetics in Q1 2025 and has held it in 5 quarters since.
  • 484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.